CURRICULUM VITAE

NAME:		William J.	Martin II, M.D.	
PRESENT ADDRESS:	Business:	 William J. Martin II, M.D. Associate Director National Institute for Environmental Health Sciences Director, Office of Translational Research National Institutes of Health 111 T.W. Alexander Drive P.O. Box 12233 Bldg. 101, Room B220, MD B2-07 Research Triangle Park, NC 		
	Telephone: Fax:	919-541-48 919-541-77	- · -	
	E-mail:	wjmartin@	niehs.nih.gov	
<u>CITIZEN</u> :		United Stat	tes	
EDUCATION: Marquette University, Milwaukee, WI University of Minnesota, Minneapolis, MN Mayo Graduate School of Medicine, Rochester, Minnesota		Degree B.S. M.D. M.S.	<u>Year Conferred</u> 1970 1974 1979	<u>Field of Study</u> Biology/Chemistry Medicine Medicine

TRAINING:

1974 -1977	Internal Medicine Residency, Mayo Graduate School of Medicine,
	Rochester, Minnesota
1977-1979	Pulmonary Subspecialty Training, Mayo Graduate School of Medicine,
	Rochester, Minnesota
1979-1981	Guest Worker, National Heart, Lung, and Blood Institute, Pulmonary
	Branch, Bethesda, Maryland
1995-1996	Health Policy Fellow, United States Senate, Labor and Human Resources
	Committee

ACADEMIC POSITION:

1979-1981	Instructor, University of Minnesota, Mayo Medical School, Rochester, Minnesota
1981-1985	Assistant Professor of Medicine, Mayo Medical School, Rochester, Minnesota
1986-1988	Associate Professor of Medicine, Mayo Medical School and Mayo Foundation,
	Rochester, Minnesota
1997-2001	Adjunct Professor, Department of Integrative Physiology, University of North
	Texas Health Science Center, Fort Worth, Texas
1981-1988	Consultant, Thoracic Diseases, Mayo Clinic, Rochester, Minnesota
1988-2000	Director, Division of Pulmonary, Allergy, Critical Care and Occupational
	Medicine, Indiana University School of Medicine, Indianapolis, Indiana
1988-2002	Professor of Medicine, Indiana University School of Medicine, Indianapolis,
	Indiana
1988-2002	Floyd and Reba Smith Chair, Indiana University School of Medicine,
	Indianapolis, Indiana
2000-2001	Associate Dean for Specialty Care, Indiana University School of Medicine,
	Indianapolis, Indiana
2000-2002	President and Chief Executive Officer, Indiana University Health Care
2001-2002	Executive Associate Dean for Clinical Affairs, Indiana University School of
	Medicine, Indianapolis, Indiana
2002-	Professor of Medicine, University of Cincinnati, Cincinnati, Ohio
2002-2003	Acting Senior Vice President for Health Affairs, University of Cincinnati,
	Cincinnati, Ohio
2002-2004	Christian R. Holmes Chair, College of Medicine, University of Cincinnati
2002-2004	Dean, College of Medicine, University of Cincinnati, Cincinnati, Ohio
2004-2006	Donald C. Harrison Chair (inaugural recipient of endowed Chair), University of
	Cincinnati, Cincinnati, Ohio
2006-	Associate Director, National Institutes of Environmental Health Sciences
	(NIEHS), Research Triangle Park, North Carolina
2006-	Director, Office of Translational Research, NIEHS, Research Triangle Park,
	North Carolina

LICENSURE:

Physician, State of Minnesota, 1974-1988
Physician, State of Iowa, 1977-1979
Physician, State of Indiana 1988-2002
Physician, State of Ohio 2002-present

AMERICAN BOARD OF CERTIFICATION:

Internal Medicine - 1977 Pulmonary Medicine - 1980

SOCIETIES:

AOA Honorary Medical Society American College of Physicians American Thoracic Society Sigma Xi American Federation for Clinical Research American College of Chest Physicians (Fellow) Indiana Thoracic Society American Lung Association of Indiana American Society for Clinical Investigation Association of American Physicians American Clinical and Climatological Association

HONORS AND OTHER SPECIAL SCIENTIFIC RECOGNITION:

Cum Laude, Marquette University National Institute of Mental Health Student Research Fellowship, 1971-1973 Minnesota Medical Foundation Research Award, 1973-1974 AOA Medical Society 1974 Parker B. Francis Fellow, 1977-1978 Minnesota Lung Association Fellow, 1978-1979 Balfour Research Award, Mayo Clinic, 1979 Mayo Foundation Scholar, Mayo Clinic, 1979-1981 Rappaport Clinical Investigator Award, Mayo Clinic, 1982-1985 American College of Chest Physicians, "Future Leaders of Pulmonary Medicine," 1983 American Society for Clinical Investigation, 1992 – present "Best Doctors" list (Town and Country magazine, Indianapolis Monthly, Cincinnati Magazine), listings from 1990 to 2004 Robert Wood Johnson Health Policy Fellowship (awarded but declined) 1995-1996 Health Policy Fellow, US Senate Labor & Human Resources Committee 1995-1996 Association of American Physicians, 1996 - present Tom Neff Honorary Lecturer, University of Colorado, 1999 President, American Thoracic Society, 2000-2001 Spirit of Indiana Award (annual award), American Lung Association of Indiana, 2000 Manuscript highlighted by National Institute of Allergy and Infectious Disease "SciBites", 2001 PNAS manuscript reviewed in Nature Reviews Immunology, 2002 Annual Leadership Award, Alpha-1 Antitrypsin Foundation, Miami, Florida, 2002 Sagamore of the Wabash Award, Highest honor for citizen of Indiana, presented by Governor O'Bannon, 2002 Inaugural recipient of William J. Martin II, M.D. Award, Public Advisory Roundtable, American Thoracic Society, 2003 Chair, Ohio Council of Medical School Deans, 2004 Grand Marshal, 32nd Annual Dr. Martin Luther King Jr. Memorial March and Ceremony, Cincinnati, OH, 2004 Elected to American Clinical and Climatological Association, 2004 David Dines Honorary Lecturer, Mayo Clinic, 2005 The President's Volunteer Service Award (Hurricane Katrina Relief with Project Hope), 2005 Pfizer Visiting Professor Award, Baylor University, 2006

SELECTED PUBLICATIONS

109. Zhu S, Kachel D, Martin II WJ, Matalon S. Nitrated SP-A does not enhance adherence of *Pneumocystis carinii* to alveolar macrophages. Am J Physiol 275(19):L1031-L9, 1998

110. Twigg III HL, Martin II W. Immunologic and non-immunologic lung defense mechanisms. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yuninger JW, eds. Allergy Principles and Practice. 5th ed. St. Louis, MO: CV Mosby Co.; 1998:477-94.

111. Perry DG, Daugherty G, Martin II WJ. Clathrin-coated pit-associated proteins are required for alveolar macrophage phagocytosis. J Immunol 162:380-6, 1999

112. Downing JF, Kachel DL, Pasula R, Martin II WJ. Gamma interferon stimulates rat alveolar macrophages to kill *Pneumocystis carinii* by L-arginine- and tumor necrosis factor-dependent mechanisms. Infect Immun 67:1347-52, 1999

113. Pasula R, Wright J, Martin II WJ. Surfactant protein A suppresses reactive nitrogen intermediates by alveolar macrophages in response to *Mycobacterium tuberculosis*. J Clin Invest 103:483-90, 1999

114. Martin II WJ, Wright J. *Pneumocystis carinii* pneumonia and pulmonary surfactant. J Lab Clin Med 133:406-7, 1999

115. Spech RW, Wisniowski P, Kachel DL, Wright JR, Martin II WJ. Surfactant protein A prevents silica-mediated toxicity to rat alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 278(4):L713-8, 2000

116. Mishra A, Doyle NA, Martin II WJ. Bleomycin-mediated pulmonary toxicity: evidence for a p53mediated response. Am J Respir Cell Mol Biol 22(5):543-9, 2000

117. Behnia M, Robertson KA, Martin II WJ. Lung infections: role of apoptosis in host defense and pathogenesis of disease. Chest 117(6):1771-7, 2000

118. Wisniowski PE, Spech RW, Wu M, Doyle NA, Pasula R, Martin II WJ. Vitronectin protects alveolar macrophages from silica toxicity. Am J Respir Crit Care Med 162(2 Pt 1):733-9, 2000

119. Martin II WJ, Pasula R. Role of alveolar macrophages in host defense against Pneumocystis carinii. Am J Respir Cell Mol Biol 23(4):434-5, 2000

120. Wu M, Kelley MR, Hansen WK, Martin II WJ. Reduction of BCNU toxicity to lung epithelial cells by high level expression of O^6 methylguanine-DNA methyltransferase. American Journal of Physiology Lung Cell Molecular Physiology 280(4):L755-L61, 2000

121. He Y-H, Kelley M, Wu M, Williams DA, Martin II WJ. Expression of yeast apurinic/apurimidinic endonuclease (APN1) protects lung endothelial cells against bleomycin toxicity. Am J Respir Cell Mol Biol 25:692-8, 2001

122. American Lung Association Asthma Clinical Research Centers [WJ Martin II PI, ACRC, Indiana University. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 345(21):1529-36, 2001

123. Wu M, Hussain S, He Y-H, Pasula R, Smith P, Martin II WJ. Genetically engineered macrophages expressing IFN-g restore alveolar immune function in scid mice. Proc Natl Acad Sci USA 98:14589-94, 2001

124. He Y-H, Xu Y, Kobune M, Wu M, Kelley MR, Martin II WJ. *Escherichia coli* FPG and human OGG1 reduce DNA damage and cytotoxicity by BCNU in human lung cells. Am J Physiol Lung Cell Mol Physiol 282:L50-L5, 2002

125. Pasula R, Wisniowski P, Martin II WJ. Fibronectin facilitates *Mycobacterium tuberculosis* attachment to murine alveolar macrophages. Infect Immun 70(3):1287-92, 2002

126. Wu M, Stockley PG, Martin II WJ. An improved Western blotting technique effectively reduces background. Electrophoresis 23:2373-6, 2002

127. Pasula R, Weaver T, Martinez M, Martin II WJ. Morphologic detection and functional assessment of reconstituted normal alveolar macrophages in the lungs of scid mice. J Immunol 169:4504-10, 2002

128. Wu M, He Y-H, Xu Y, Kobune M, Kelley MR, Williams DA, Martin II WJ. Protection of human lung cells against hyperoxia using the DNA base excision repair genes hOgg1 and Fpg. Am J Respir Crit Care Med 166:192-9, 2002

129. Hussain S, Wright JR, Martin II WJ. Surfactant protein A decreases nitric oxide production by macrophages in a tumor necrosis factor-a-dependent mechanism. Am J Respir Cell Mol Biol 28:520-7, 2003

130. Boulware D, Forger W, Martin II WJ. Medical risks of wilderness hiking. Am J Med 114(4):288-93, 2003

131. Wu M, Pasula R, Smith P, Martin II WJ. Mapping alveolar binding sites *in vivo* using phage peptide libraries. Gene Ther 10:1429-36, 2003

132. Zhang D, Wu M, Nelson D, Pasula R, Martin II WJ. Alpha-1-antitrypsin expression in lung is increased by airway delivery of gene-transfected macrophages. Gene Ther 10:2148-52, 2003

133. Day R, Wang Y, Knox K, Pasula R, Martin II WJ, Twigg III HL. Alveolar macrophages from HIV infected subjects are resistant to *Mycobacterium tuberculosis in vitro*. Am J Respir Cell Mol Biol 30:403-10, 2004

134. Martin II WJ, Iannuzzi MC, Gail DB, Peavy HH. NHLBI Working Group: Future Directions in Sarcoidosis Research. Am J Respir Crit Care Med 170:567-71, 2004

135. Camus P, Martin II WJ, Rosenow E. Amiodarone Pulmonary Toxicity. Clin Chest Med 1:65-75, 2004

136. Martin II WJ, Wu M, Pasula R. A novel approach to restore lung immunity during systemic immunosuppression. Trans Am Clin Climatol Assoc 116:221-7, 2005

137. Schwartz DA, Martin II, WJ. NIEHS Director's perspective. Translating Translational Biomedicine for Environmental Health. Environ Health Perspective 114: A206, 2006

138. Schwartz DA. Martin II, WJ NIEHS Director's perspective. HEALing in New Orleans. Environmental Health Perspective 114: A570, 2006

139. Schwartz DA. Martin II, WJ NIEHS Director's perspective. Focusing on Global Environmental Health. Environmental Health Perspective 114: A630, 2006

140. Mullen M, Wetzel CC, Parks J, Mark L, Martin II WJ. New Simplified Approach for Cell-Based Therapy to the Lung. (In revision), 2007

141. Pasula R, Martin II WJ. Reconstitution of activated alveolar macrophages into the lungs of SCID mice reduces *Pneumocystis carinii* infection. (Submitted) 2007

142. Martin II WJ, Mullen M, Wetzel CC, Morris R. Airway delivery of donor type II alveolar epithelial cells in bleomycin-injured mice. (Submitted) 2007f